menu
    • menu

    Company profile for Mabwell

    NEW Drugs in Dev: 27
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mabwell (688062.SH), an innovation-driven biopharmaceutical company, has the whole industrial chain of R&D, manufacturing, and commercialization. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established....
    Mabwell (688062.SH), an innovation-driven biopharmaceutical company, has the whole industrial chain of R&D, manufacturing, and commercialization. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 14 pipeline products in different R&D stages based on a world-class and state-of-the-art R&D engine, including 10 novel drug candidates and 4 biosimilars.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MabwellChina Flag
    Country
    Country
    China
    Address
    Address
    Building 3, Creative Park, No. 576 Libing Road, Pudong New Area, Shanghai
    Telephone
    Telephone
    021-58585793
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mabwell.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mabwell Gets NMPA Approval for Denosumab in New Indications
    Mabwell Gets NMPA Approval for Denosumab in New Indications

    21 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mabwell-announces-nmpa-approval-of-supplemental-application-for-additional-indications-of-maiweijian-denosumab-injection-302778306.html

    PR NEWSWIRE
    21 May 2026
    Share Share
    Mabwell to Present 9MW2821 Data for Cervical Cancer at ESMO 2026
    Mabwell to Present 9MW2821 Data for Cervical Cancer at ESMO 2026

    30 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/2026-esmo-gc--mabwell-to-present-latest-clinical-data-on-9mw2821-for-cervical-cancer-in-oral-and-poster-presentations-302758286.html

    PR NEWSWIRE
    30 Apr 2026
    Share Share
    Mabwell Starts Phase III Trial For Nectin-4 ADC 9MW2821
    Mabwell Starts Phase III Trial For Nectin-4 ADC 9MW2821

    23 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mabwell-initiates-phase-iii-clinical-study-of-its-nectin-4-targeting-adc-9mw2821-for-the-treatment-of-triple-negative-breast-cancer-302751535.html

    PR NEWSWIRE
    23 Apr 2026
    Share Share
    NMPA Accepts Mabwell's SBLA for MAIWEIJIAN (Denosumab)
    NMPA Accepts Mabwell's SBLA for MAIWEIJIAN (Denosumab)

    16 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7181847

    FIRSTWORD PHARMA
    16 Apr 2026
    Share Share
    Mabwell Inks Deal For Denosumab Biosimilar Commercialization
    Mabwell Inks Deal For Denosumab Biosimilar Commercialization

    16 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mabwell-establishes-a-licensing-and-commercialization-agreement-for-denosumab-biosimilars-in-malaysian-market-302744512.html

    PR NEWSWIRE
    16 Apr 2026
    Share Share
    Mabwell's LILRB4/CD3 TCE Antibody IND Accepted By NMPA
    Mabwell's LILRB4/CD3 TCE Antibody IND Accepted By NMPA

    15 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/global-first--nmpa-accepts-ind-application-for-mabwells-innovative-lilrb4cd3-tce-bispecific-antibody-6mw5311-302744036.html

    PR NEWSWIRE
    15 Apr 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search